Get 50% OFF This Summer!

Advertisement
logo

Valiant Laboratories

VALIANTLAB
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Valiant Laboratories Share price and Fundamental Analysis

View All Details
View All Details
Valiant Laboratories Limited was originally formed as a Partnership Firm under the name and style of M/s. Bharat Chemicals' through Deed of Partnership dated October 17, 1980. The said Partnership Firm, M/s. Bharat Chemicals thereafter converted into a Public Limited Company with the name 'Valiant Laboratories Limited' through certificate of incorporation dated August 16, 2021 issued by the Central Registration Centre, Registrar of Companies.
Company Incorporation2021
ChairmanVelji Gogri
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
431.28
PE Ratio
0
Industry P/E
35.07
PEG Ratio
0
ROE
-4.31%
ROCE
-3.31%
ROA
-1.15%
Total Debt (Cr)
115.58
Debt to Equity
0.5
Dividend Yield
0%
EPS
0
Book Value & P/B
53.31 x 1.86
Face Value
10
Outstanding Shares(Cr)
4.35
Current Ratio
17.1
EV to Sales
4.03

Stock Returns

1 Week-5.65%
1 Month+1.54%
6 Months-16.52%
1 Year-35.17%
3 Years-44.25%
5 Years-44.25%

CAGR

1 Year CAGR

Revenue Growth

-45.48%

Net Profit Growth

-98.9%

Operating Profit Growth

-96.81%

Dividend Growth

N/A

Stock Returns CAGR

-35.17%
no_data

No Stocks

Smart Score

1.4
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 74.94%

FIIs : 0.64%

DIIs : 0.00%

Public : 24.42%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
FII Shareholding Increased by 0.64% to 0.64% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Valiant Laboratories Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Valiant Laboratories Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Valiant Laboratories Limited was originally formed as a Partnership Firm under the name and style of M/s. Bharat Chemicals' through Deed of Partnership dated October 17, 1980. The said Partnership Firm, M/s. Bharat Chemicals thereafter converted into a Public Limited Company with the name 'Valiant Laboratories Limited' through certificate of incorporation dated August 16, 2021 issued by the Central Registration Centre, Registrar of Companies.

The Company is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. The Company gradually, commenced manufacturing of Paracetamol by late 1982. Paracetamol (Scientific name: Acetaminophen or para-hydroxyacetanilide - C8H9NO2), is one of the most commonly taken analgesic worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO). Paracetamol has several applications such as usage in treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold and fever. It manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of customers.

Paracetamol is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms. Paracetamol is often found combined with other drugs in many over the counter (OTC) allergy medications, cold medications, sleep medications, pain relievers, and other products.

Presently, the Company is engaged in manufacturing and dealing in Pharmaceuticals and specility chemicals. The manufacturing facility is located at Tarapur Industrial Area, Boisar in the State of Maharashtra, with an annual installed capacity of 9,000 MTPA. Within the Manufacturing Facility located at Tarapur Industrial Area, Palghar, Maharashtra, the Company has an in-house R&D infrastructure which is equipped with analytical laboratory and infrastructure for developmental activities in existing product. The Company is promoted by Shantilal Shivji Vora, Director and Dhanvallabh Ventures LLP (DVL).

In July, 2022 the Company formed its wholly owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL) to diversify the business activities.

The Company has come out with a Public Issue of issuing upto 11,556,000 Equity Shares through fresh issue.

Valiant Laboratories Share Price

Valiant Laboratories share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Valiant Laboratories Market Cap

Market capitalization of Valiant Laboratories indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Valiant Laboratories is valued compared to its competitors.

Valiant Laboratories PE Ratio

Valiant Laboratories PE ratio helps investors understand what is the market value of each stock compared to Valiant Laboratories 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Valiant Laboratories PEG Ratio

The PEG ratio of Valiant Laboratories evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Valiant Laboratories ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Valiant Laboratories generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Valiant Laboratories ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Valiant Laboratories in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Valiant Laboratories Total Debt

Total debt of Valiant Laboratories shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Valiant Laboratories Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Valiant Laboratories compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Valiant Laboratories CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Valiant Laboratories over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Valiant Laboratories Technical Analysis

Technical analysis of Valiant Laboratories helps investors get an insight into when they can enter or exit the stock. Key components of Valiant Laboratories Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Valiant Laboratories shares often struggle to rise above due to selling pressure.

Valiant Laboratories Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Valiant Laboratories ’s financial health and profitability.

Valiant Laboratories Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Valiant Laboratories Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Valiant Laboratories Financials

The financials of Valiant Laboratories provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Valiant Laboratories Profit and Loss Statements

The profit and loss statement of Valiant Laboratories highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Valiant Laboratories .

Valiant Laboratories Balance Sheet

The balance sheet presents a snapshot of Valiant Laboratories ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Valiant Laboratories Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App